Journal
EPIGENOMICS
Volume 4, Issue 6, Pages 675-683Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/EPI.12.64
Keywords
breast cancer; ChIP-seq; chromatin; chromatin landscape; DNA methylation; endocrine therapy resistance; epigenetic; epigenomic; estrogen receptor; histone modification; hormonal therapy; pioneer factors
Categories
Ask authors/readers for more resources
Over two-thirds of breast cancers rely on estrogen receptor alpha (ER alpha) for their growth. Endocrine therapies antagonize estrogen-dependent ER alpha activation but resistance to these treatments occurs and is associated with poor prognosis. Crosstalk between alternative survival pathways and ER alpha are currently held as the primary cause of resistance. However, blocking these pathways does not cure endocrine therapy resistant breast cancer suggesting the existence of additional mechanisms. While cancer is commonly considered a genetic disease, the importance of epigenetic events in promoting tumor initiation and progression is increasingly recognized. Here, we consider how epigenetic modifications and alterations to the chromatin landscape contribute to endocrine therapy resistance by modulating ER alpha expression or altering its genomic activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available